Literature DB >> 6664462

In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine.

S R Philips, A M Robson.   

Abstract

The in vivo release of endogenous dopamine (DA) from the rat caudate nucleus has been measured in the presence and absence of beta-phenylethylamine. A push-pull cannula was implanted into the brain and the tissue was perfused with artificial cerebrospinal fluid (CSF) containing phenylethylamine in concentrations ranging from 5 X 10(-3) to 5 X 10(-7) M. The DA released into the perfusate was determined radioenzymatically. Dopamine was released at rates significantly greater than its resting rate by concentrations of phenylethylamine of 5 X 10(-3) to 5 X 10(-5)M; 5 X 10(-6)M phenylethylamine caused a slight increase in release, but the difference from the resting rate was not significant. The absence of calcium in the perfusing medium did not significantly alter either the unstimulated release rate of DA or the release rate stimulated by 5 X 10(-5)M phenylethylamine. The concentrations of phenylethylamine required to increase release of DA in vivo are discussed briefly in relation to the doses required to elicit behavioural effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6664462     DOI: 10.1016/0028-3908(83)90203-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

2.  Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells.

Authors:  Ada Ledonne; Mauro Federici; Michela Giustizieri; Mauro Pessia; Paola Imbrici; Mark J Millan; Giorgio Bernardi; Nicola B Mercuri
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

3.  Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat.

Authors:  T Kuroki; T Tsutsumi; M Hirano; T Matsumoto; Y Tatebayashi; K Nishiyama; H Uchimura; A Shiraishi; T Nakahara; K Nakamura
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.

Authors:  I Lamensdorf; S Porat; R Simantov; J P Finberg
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

6.  Determination of regional distributions of phenylethylamine and meta- and para-tyramine in rat brain regions and presence in human and dog plasma by an ultra-sensitive negative chemical ion gas chromatography-mass spectrometric (NCI-GC-MS) method.

Authors:  D A Durden; B A Davis
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

7.  Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors:  G B Baker; R T Coutts; T S Rao
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

8.  Down-regulation of beta-adrenergic and dopaminergic receptors induced by 2-phenylethylamine.

Authors:  P R Paetsch; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1993-06       Impact factor: 5.046

Review 9.  2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action.

Authors:  P R Paetsch; A J Greenshaw
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.